Forest Laboratories to Discontinue NAMENDA Tablets, Focus on Once-Daily NAMENDA XR

17-02-2014 Business Wire HealthComments (0)

Forest LaboratoriesPharmaceutical

Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014. Forest has notified the U.S. Food and Drug Administration of this decision. The oral solution of NAMENDA and once-daily NAMENDA XR (memantine HCl) extended-release capsules will continue to be a

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top